Cristina Gómez-Marín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cristina Gómez-Marín has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Miralles
Institute of Food Science Research CIAL (CSIC-UAM), Madrid, Spain
3 shared publications - Isidra Recio
Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC-UAM, CEI UAM+CSIC), Nicolás Cabrera, 9, 28049 Madrid, Spain
3 shared publications - Santiaga María Vivanco-Maroto
Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC-UAM, CEI UAM+CSIC), Nicolás Cabrera, 9, 28049 Madrid, Spain
2 shared publications - Cristina Ramirez
Gastroenterology Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain
1 shared publication Hans H. Stein
1 shared publication- Irene Soleto
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
1 shared publication
Latest Publications
- Open Access
- 15 March 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 12
Age-dependent plant protein digestibility and implications for epitope generation and hormonal secretion
- 15 March 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 12
Open AccessAge-dependent plant protein digestibility and implications for epitope generation and hormonal secretion
- Open Access
- 13 January 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 12
In vitro protein digestibility of plant-based foods and ingredients vs standardized values in growing pigs
- 13 January 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 12
Open AccessIn vitro protein digestibility of plant-based foods and ingredients vs standardized values in growing pigs
- Open Access
- 29 May 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (13) , 5301-5311
Milk peptides found in human jejunum induce enteroendocrine hormone secretion and inhibit DPP-IV
The strong effect of protein digestion products on gastrointestinal hormone release is well recognized.
- 29 May 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (13) , 5301-5311
Open AccessMilk peptides found in human jejunum induce enteroendocrine hormone secretion and inhibit DPP-IV
The strong effect of protein digestion products on gastrointestinal hormone release is well recognized.
- Open Access
- 18 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2831
Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear. This study aimed to assess the expression of various homing markers and the migratory abilities of circulating DC subsets in response to intestinal chemotactic signals. Additionally, this study examined how golimumab and ustekinumab impact these characteristics in individuals with IBD compared to healthy controls. The findings revealed that a particular subset of DCs known as type 2 conventional DCs (cDC2) displayed a more pronounced migratory profile compared to other DC subsets. Furthermore, the study observed that golimumab and ustekinumab had varying effects on the migratory profile of cDC1 in individuals with CD and UC. While CCL2 did not exert a chemoattractant effect on DC subsets in this patient cohort, treatment with golimumab and ustekinumab enhanced their migratory capacity towards CCL2 and CCL25 while reducing their migration towards MadCam1. In conclusion, this study highlights that cDC2 exhibits a heightened migratory profile towards the gastrointestinal mucosa compared to other DC subsets. This finding could be explored further for the development of new diagnostic biomarkers or the identification of potential immunomodulatory targets in the context of IBD.
- 18 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2831
Open AccessEffects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear. This study aimed to assess the expression of various homing markers and the migratory abilities of circulating DC subsets in response to intestinal chemotactic signals. Additionally, this study examined how golimumab and ustekinumab impact these characteristics in individuals with IBD compared to healthy controls. The findings revealed that a particular subset of DCs known as type 2 conventional DCs (cDC2) displayed a more pronounced migratory profile compared to other DC subsets. Furthermore, the study observed that golimumab and ustekinumab had varying effects on the migratory profile of cDC1 in individuals with CD and UC. While CCL2 did not exert a chemoattractant effect on DC subsets in this patient cohort, treatment with golimumab and ustekinumab enhanced their migratory capacity towards CCL2 and CCL25 while reducing their migration towards MadCam1. In conclusion, this study highlights that cDC2 exhibits a heightened migratory profile towards the gastrointestinal mucosa compared to other DC subsets. This finding could be explored further for the development of new diagnostic biomarkers or the identification of potential immunomodulatory targets in the context of IBD.